Preprint Article Version 2 Preserved in Portico This version is not peer-reviewed

Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma

Ismail Khan
,
Zafar Iqbal
,
Abad Khan
* ORCID logo ,
Lateef Ahmad
,
Amjad Khan
,
Saeed Ahmad Khan
,
Muhammad Delwar Hussain
,
Mohsin Kazi
* ORCID logo
Version 1 : Received: 17 August 2023 / Approved: 17 August 2023 / Online: 17 August 2023 (11:55:20 CEST)
Version 2 : Received: 16 December 2023 / Approved: 18 December 2023 / Online: 19 December 2023 (02:20:56 CET)

How to cite: Khan, I.; Iqbal, Z.; Khan, A.; Ahmad, L.; Khan, A.; Khan, S.A.; Hussain, M.D.; Kazi, M. Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma. Preprints 2023, 2023081277. https://doi.org/10.20944/preprints202308.1277.v2 Khan, I.; Iqbal, Z.; Khan, A.; Ahmad, L.; Khan, A.; Khan, S.A.; Hussain, M.D.; Kazi, M. Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma. Preprints 2023, 2023081277. https://doi.org/10.20944/preprints202308.1277.v2

Abstract

This study was to designed to develop sorafenib-loaded polymeric nanoparticles, surface-modified with pluronic F-127 for the effective treatment of hepatocellular (HCC) and renal cell carcinomas (RCC). Poly lactic coglycolic acid (PLGA) was used to encapsulate different concentrations of sorafenib by a simple modified solvent evaporation method applying pluronic F-127 as a surfactant and coating agent. The preformulation and characterization studies were conducted to evaluate the incompatibilities among sorafenib, PLGA and pluronic F-127, and physicochemical properties of the formulations, respectively. The sizes of the coated and plain PLGA nanoparticles were ~140 ± 14.7 nm and ~ 120 ± 10.1 nm, respectively. It has been confirmed from the in vitro release studies that PLGA sustained the release of sorafenib, avoiding the initial burst release, while the in vivo studies demonstared that surface-modified nanoparticles have greater affinity in the target aorgans than plain PLGA nanoparticles and free drug keeping the dose constant (20 mg/kg body weight). The delivery of sorafenib-loaded polymeric PLGA nanoparticles into the target tissues and their pharmacokinetic parameters have been improved significantly compared to the reported formulations.

Keywords

Sorafenib; PLGA; Pluronic F-127; Nanosuspensions; In-vitro release; In-vivo pharmacokinetics

Subject

Public Health and Healthcare, Primary Health Care

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.